GSK - GSK plc

NYSE - Nasdaq Real Time Price. Currency in USD
34.11
+0.31 (+0.92%)
At close: 04:00PM EDT
34.00 -0.11 (-0.32%)
After hours: 07:30PM EDT
Stock chart is not supported by your current browser
Previous Close33.80
Open33.95
Bid34.00 x 1100
Ask34.16 x 3200
Day's Range33.88 - 34.25
52 Week Range28.47 - 44.75
Volume1,990,741
Avg. Volume2,889,204
Market Cap69.84B
Beta (5Y Monthly)0.28
PE Ratio (TTM)12.49
EPS (TTM)2.73
Earnings DateFeb 01, 2017 - Feb 06, 2017
Forward Dividend & Yield1.39 (4.12%)
Ex-Dividend DateMay 18, 2023
1y Target Est40.00
  • Simply Wall St.

    Investors in GSK (LON:GSK) have unfortunately lost 19% over the last year

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...

  • Business Wire

    GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US

    PHILADELPHIA, June 01, 2023--GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US

  • Reuters

    UPDATE 2-US FDA approves Pfizer's RSV vaccine

    The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot. In a late-stage study, Pfizer's vaccine, to be sold under the brand name Abrysvo, was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.

  • CNW Group

    Biopharma company GSK grants $1 million to Halifax-based Canadian Center for Vaccinology (CCfV)

    GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.

  • Reuters

    UPDATE 2-US FDA panel backs Pfizer's maternal RSV vaccine for protecting infants

    Advisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness. The FDA's advisory committee voted unanimously that available data supported the vaccine's efficacy for giving the shot to women in their second or third trimesters of pregnancy to prevent lower respiratory tract infection and severe disease in infants up to 6 months of age. The expert panel voted 10-4 that the data also supports the safety of the vaccine for that patient population, paving the way for likely U.S. approval.

  • Reuters

    US FDA advisers to discuss Pfizer's maternal RSV vaccine

    Advisers to the U.S. Food and Drug Administration on Thursday will discuss Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers. An estimated 58,000 to 80,000 children under 5 years old are hospitalized due to RSV infection annually in the United States, according to government data. The agency's staff reviewers on Tuesday deemed the safety data for Pfizer's vaccine "generally favorable".

  • Business Wire

    BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

    MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl

  • Reuters

    UPDATE 3-US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

    The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.

  • Reuters

    US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

    The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.

  • Simply Wall St.

    Interested In GSK's (LON:GSK) Upcoming UK£0.14 Dividend? You Have Four Days Left

    GSK plc ( LON:GSK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day before...

  • Yahoo Finance UK

    Trending tickers: GSK | THG | Beazley | Disney

    The latest investor updates on stocks that are trending on Friday.

  • Yahoo Finance UK

    Wall Street loses ground as FTSE 100 closes higher on UK economy growth

    FTSE 100 closes the week higher as the UK economy returned to growth.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

    STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple my

  • Motley Fool

    The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

    Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

  • GlobeNewswire

    SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

    SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone payments of up to $503 million and tiered royalties.SCYNEXIS ended Q1 with cash, cash equivalents and short-term investments of $54.8 million, and upon receipt of the upfront payment from GSK will have a projecte

  • Simply Wall St.

    GSK plc (LON:GSK) is favoured by institutional owners who hold 82% of the company

    Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...

  • CNW Group

    $3 million joint investment by GSK and U of T to launch the GSK Chair in Vaccine Education and Practice-Oriented Tools

    The University of Toronto (U of T) and biopharma company GSK are investing $3 million for the creation of a new chair that will enhance and develop vaccine education programs and practice tools for pharmacists and other health professionals. GSK is providing $2 million, while U of T's Leslie Dan Faculty of Pharmacy is pitching in $1 million.

  • Yahoo Finance Video

    GSK’s vaccine against RSV wins FDA approval

    Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the FDA’s approval of GlaxoSmithKline’s (GSK) vaccine against RSV.

  • Reuters

    PRESS DIGEST- New York Times business news - May 4

    The Federal Trade Commission (FTC) escalated its fight with the tech industry's biggest companies as it moved to impose what it called a "blanket prohibition" on the collection of young people's personal data by Meta Platforms Inc. - The U.S. Senate voted on Wednesday to reinstate tariffs on solar panels from Chinese companies in Southeast Asia that had been found to be coming into the United States in violation of trade rules.

  • Business Wire

    US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

    PHILADELPHIA, May 03, 2023--US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

  • Reuters

    UPDATE 3-US FDA approves first RSV vaccine from GSK

    The U.S. Food and Drug Administration has approved GSK Plc's respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people. The approval makes GSK, which has been neck-and-neck with Pfizer in RSV vaccine development, the first company to tap into a multi-billion-dollar market and also puts it ahead of rivals such as Moderna Inc and Bavarian Nordic. Credit Suisse analysts expect $2.5 billion in peak sales for GSK's RSV vaccine for older adults.

  • The Telegraph

    Investors may be sceptical, but this unloved stock has much to offer – and a lowly valuation

    Here is an unloved stock that offers a new group structure, the potential resolution of legal woes, the presence of an activist investor, a clear strategy, a building pipeline of vaccines and medicines – and all with a lowly valuation.

  • Yahoo Finance

    Pfizer to shift focus to new products amid decline in COVID sales

    Pfizer reported strong earnings for the first quarter of the year, despite a decrease in COVID product demand. However, investors are wary of the company's anticipated product launches this year.

  • Yahoo Finance Video

    Why the human genome could be health care’s holy grail

    23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe

  • Yahoo Finance

    23andMe CEO: We see more opportunities in DNA partnerships

    23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.